Elmind Capital LP purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund purchased 452,340 shares of the company’s stock, valued at approximately $26,294,524. Vaxcyte comprises about 0.0% of Elmind Capital LP’s portfolio, making the stock its 5th largest holding. Elmind Capital LP owned approximately 0.30% of Vaxcyte as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Vaxcyte during the second quarter worth $701,520,000. Janus Henderson Group PLC raised its stake in shares of Vaxcyte by 23.8% during the first quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after purchasing an additional 3,188,687 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Vaxcyte by 35.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,296,333 shares of the company’s stock valued at $521,213,000 after buying an additional 2,981,038 shares in the last quarter. Caligan Partners LP bought a new position in Vaxcyte in the 4th quarter worth approximately $78,660,000. Finally, Adage Capital Partners GP L.L.C. lifted its position in shares of Vaxcyte by 418.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock worth $79,592,000 after purchasing an additional 1,392,000 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $57.28, for a total value of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares in the company, valued at approximately $5,979,745.60. The trade was a 8.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet S. Dhaliwal sold 17,000 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the transaction, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. The trade was a 18.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 120,646 shares of company stock valued at $6,570,810 over the last 90 days. 3.30% of the stock is owned by insiders.
Vaxcyte Stock Performance
Vaxcyte (NASDAQ:PCVX – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period last year, the company earned ($1.22) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -7.6 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.
Get Our Latest Stock Analysis on Vaxcyte
Vaxcyte Company Profile
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Articles
- Five stocks we like better than Vaxcyte
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
